← All Signals

🏥 FDA: Radnostix — Class III

healthcareneutralSource: FDA
70%Confidence
0Views
FDASource
2026-04-11Date

Summary

Radnostix's Class III recall for a Sodium Iodide I-131 kit due to failed specifications involves a niche diagnostic product, posing minimal market impact but highlighting quality lapses. This may affect small-scale nuclear medicine operations and require replacement sourcing.

Actionable: Verify the availability of alternative I-131 kits for medical facilities to avoid diagnostic delays.

AI Confidence: 70%

Data Points

firmRadnostix
classificationClass III
statusOngoing
distributionNationwide in the US, including Puerto Rico
productGelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, Internation

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now